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Abstract
Background: People with diabetic retinopathy tend to have lower levels of health-related quality of life than
individuals with no retinopathy. Strategies for screening and treatment have been shown to be cost-effective. In order
to reduce the bias in cost-effectiveness estimates, systematic reviews of health state utility values (HSUVs) are crucial
for health technology assessment and the development of decision analytic models. A review and synthesis of HSUVs
for the different stages of disease progression in diabetic retinopathy has not previously been conducted.
Methods/Design: We will conduct a systematic review of the available literature that reports HSUVs for people with
diabetic retinopathy, in correspondence with current stage of disease progression and/or visual acuity. We will search
Medline, EMBASE, Web of Science, Cost-Effectiveness Analysis Registry, Centre for Reviews and Dissemination
Database, and EconLit to identify relevant English-language articles. Data will subsequently be synthesized using
linear mixed effects modeling meta-regression. Additionally, reported disease severity classifications will be mapped
to a four-level grading scale for diabetic retinopathy.
Discussion: The systematic review and meta-analysis will provide important evidence for future model-based
economic evaluations of technologies for diabetic retinopathy. The meta-regression will enable the estimation of
utility values at different disease stages for patients with particular characteristics and will also highlight where the
design of the study and HSUV instrument have influenced the reported utility values. We believe this protocol to be
the first of its kind to be published.
Systematic review registration: PROSPERO CRD42014012891
Keywords: Systematic review, Utility, Economic evaluation, Cost-utility analysis, Diabetic retinopathy,
Meta-regression, Modeling, Health technology assessment
Background
Diabetic retinopathy is one of the most common causes
of blindness [1,2], but effective and cost-effective pre-
ventive and remedial interventions are available [3,4].
When a new technology is developed, an economic eval-
uation is often conducted to determine whether it is cost-
effective. It is common for such economic evaluations
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to require decision modeling, where evidence is synthe-
sized to determine long-term costs and health benefits. In
order to minimize bias in these decision problems, it is
crucial that the process of selecting the evidence for the
model is robust, transparent, and systematic [5]. This is a
requirement of the National Institute for Health and Care
Excellence (NICE), which publishes guidance for the NHS
based on the clinical and cost-effectiveness evidence for
health technologies [6]. NICE identify quality-adjusted life
years (QALYs) as their preferred measure of health out-
come; an economic evaluation using QALYs is known as a
cost-utility analysis. QALYs combine quantity and quality
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of life, and the quality aspect is captured using health state
utility values (HSUVs). HSUVs are generally measured on
a scale anchored at 1 and 0, where 1 corresponds to ‘full
health’ and 0 represents a health state of equivalent value
to being dead.
It has been identified that many submissions to NICE
do not satisfy their requirements with regard to the
transparent and systematic selection of HSUVs [7]. A
growing number of systematic reviews are being car-
ried out to inform better selection of HSUVs [8-28],
with some synthesizing the data using meta-analysis
[9-12,14,15,17,18,22,24-26]. Such an approach is increas-
ingly being seen as an important step in the process of a
model-based economic evaluation [29].
In modeling studies of diabetic retinopathy, some
researchers choose HSUVs based on estimated visual acu-
ity levels, rather than on the disease state itself [28,30].
It is unclear whether or not the effect of visual acuity on
HSUVs is consistent across different visual disorders [31].
Any given level of visual acuity may be associated with dif-
ferent levels of health-related quality of life because of the
diverse impacts of disease on vision; whether the effect is
on central or peripheral vision may be of greater import,
for example. Therefore, such an approach is unlikely to be
valid in accurately estimating the impact of an interven-
tion on health-related quality of life. For diabetic retinopa-
thy, treatment pathways are usually defined by severity of
disease, rather than visual acuity. As such, most modeling
studies differentiate between health states based on this
and therefore need appropriate HSUVs for these disease
states.
Disease progression in diabetic retinopathy (DR) is clas-
sified in a number of ways. Often these classifications
relate to whether the disease is proliferative (PDR) or
non-proliferative (NPDR). In the USA, the most common
classification system has five or six levels (no DR/mild
NPDR/moderate NPDR/severe NPDR/PDR/PDR with
high-risk characteristics), as proposed by the American
Academy of Ophthalmology [32]. The NHS Diabetic Eye
Screening Programme (NDESP) in the UK uses four levels
(no DR/background DR/pre-proliferative DR/PDR) [33].
The Early Treatment Diabetic Retinopathy Study used
a more detailed grading system [34]. It is also possi-
ble to classify disease based on outcome or manage-
ment pathways; the Liverpool Diabetic Eye Study, for
example, uses seven levels relating to screening, referral
and treatment [35]. Other systems include the Scottish
Diabetic Retinopathy Grading Scheme, the Royal College
of Ophthalmologists grading system and feature-specific
grading.
We will carry out a systematic review and meta-analysis
in order to identify whether or not individuals with dif-
ferent levels of diabetic retinopathy have different HSUVs
and, if they do, what these levels are. Although our focus
is upon HSUVs associated with specific stages of disease
progression in DR, we will also review HSUVs associated
with visual function in people with DR. A meta-analysis
will be carried out to enablemodelers to estimate themost
appropriate HSUVs with which to populate their models.
The primary purpose of this review will be to inform the
development of a decision model to evaluate alternative
strategies in screening for diabetic retinopathy in a general
population of people with diabetes. However, the study is
designed such that it can inform future model-based eval-
uations of any intervention for diabetic retinopathy. The
study as such has a number of aims:
1. To provide a narrative overview of published studies
reporting HSUVs for diabetic retinopathy.
2. To derive pooled estimates for HSUVs that
correspond to disease states based on the most
commonly used disease classification systems.
3. To quantify the effects on reported HSUVs of
variation in study design.
4. To map reported values to a consistent grading scale
for use in a modeling study.
Methods/Design
Guidelines such as the PRISMA statement [36] are not
wholly applicable to the review, though we have developed
our methods in line with published recommendations
[37-41] where appropriate. The Patient, Intervention,
Comparison, Outcome (PICO) question is not usually
applicable to reviews of health state utility values [29].
For example, this review should not focus on a specific
intervention or comparison. Furthermore, it is also neces-
sary to define additional requirements; for example, it is
important to define which HSUV elicitation methods will
be included. This protocol is registered with Prospective
Register of Systematic Reviews (PROSPERO; registration
number: CRD42014012891). Our analysis will not require
approval from an ethics committee or written informed
consent because it relies entirely on published sample-
level data.
Search strategy
Our search will be necessarily broad due to inconsis-
tency in the nature and reporting of studies that include
HSUVs. Databases for searching will include Medline,
EMBASE, Web of Science, Cost-Effectiveness Analysis
Registry, Centre for Reviews and Dissemination Database,
and EconLit. Specific pre-defined thesaurus terms for
HSUVs do not exist, though broader termsmay apply. Our
search will use general, instrument-specific and method-
specific terms, which will be combined with terms for
diabetic retinopathy. Diabetic retinopathy is a term which
is used to describe progressive retinal changes (for exam-
ple no DR/background DR/preproliferative DR/PDR) but
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is also used broadly to cover diabetic retinopathy and
maculopathy. We will include studies that report HSUVs
for maculopathy. Given that HSUVs are often reported as
secondary outcomes, it is likely that they will not be men-
tioned in titles or abstracts. As such it will be necessary to
carry out full text searches. Additional file 1 outlines the
search terms we will use. No date or language restrictions
will be applied to the electronic searches. We will subse-
quently carry out citation searches and author searches
based on the identified papers. Colleagues will be asked to
comment on the completeness of the final list of studies.
We will additionally carry out a search for grey literature
using our specified terms on a number of specific tools:
SHERPA Search [42], Research Papers in Economics [43],
and Open Grey [44].
Study eligibility
Inclusion criteria
Studies of any design will be included, and it is expected
that all will be categorized as either clinical decision analy-
ses or outcomes studies. Clinical decision analysis studies
will include randomized controlled trials and economic
evaluations, while outcomes studies are those designed
specifically to elicit HSUVs.
Studies must use a recognized method of direct (for
example, standard gamble or time tradeoff ) or indirect
(for example, EQ-5D or Health Utilities Index) utility
assessment. HSUVs from visual analog scales, mapping
algorithms, and expert opinion will also be included. The
language of publication must be English.
All types of publication (both full publications and
abstracts) will be included. The population will be people
with diabetic retinopathy or those attending screening for
diabetic retinopathy. There are no inclusion criteria relat-
ing to specific interventions or technologies. The com-
parator element of the PICO statement does not apply.
The studies must report either mean or median HSUVs
and these must relate either to visual function or disease
states specific to diabetic retinopathy. Such disease states
are likely to be based on the grading systems described
above, though studies adopting other retinopathy grading
systems will be included.
Exclusion criteria
We will exclude editorials, reviews, and meta-analyses
that do not report original data. Studies that report data
from health state classification systems but do not esti-
mate HSUVs will be excluded.
Data collection
Study selection
The first reviewer (CJS) will assess studies for retrieval
based on titles and abstracts. The second reviewer (JCT)
will check the validity of exclusions. Any disagreements
will be resolved by discussion. It is likely that many titles
and abstracts will not mentionHSUVs, despite their inclu-
sion. Indeed, it has been reported that rejecting studies
based on title and abstract can result in lost citations when
reviewing HSUVs [37]. Articles will be rejected based on
the title and abstract only if it is clear that the study
could not have recorded the necessary data for inclu-
sion. Full texts will be retrieved for studies not rejected
at abstract screening. These will be assessed by the first
reviewer for satisfaction of the inclusion and exclusion
criteria. Reasons for exclusion will be recorded, and the
second reviewer will check the validity of exclusions.
The number of records identified, retrieved, screened,
assessed, included, and excluded in the review, and rea-
sons for exclusions, will be summarized in a PRISMA flow
diagram [36].
Data extraction andmanagement
Data will be extracted by the first reviewer (CJS) using
the electronic data extraction form shown in Additional
file 2, and automatically recorded in a spreadsheet. A sep-
arate form will be completed for each reported HSUV as
studiesmay include different subpopulations; for example,
from different countries. Extracted data will subsequently
be crosschecked by the second reviewer (JCT). Any dis-
agreements will be resolved by discussion until consensus
is reached. Based on previous reviews of HSUVs (cited
above), we will record the following for each study: first
author, publication year, study title, publication name,
study design, interventions/comparators, sample size, and
the number of separate HSUVs reported in the paper. For
each reported HSUV, we will record point estimate type
(mean/median), reportedHSUV,measure of variance type
(standard deviation/variance), reported variance statis-
tic, retinopathy state, maculopathy state, grading system
used, visual function measurement method, visual acu-
ity/function level, sample size, country, age range, other
sample specifics, valuation method, valuation source,
value set country, upper anchor, lower anchor, adminis-
tration method, study arm, and treatment status. Where
data are reported for individuals without retinopathy - for
example, for those attending screening - these data will
also be recorded. The data extraction form has been suc-
cessfully piloted on three pre-identified studies. Where
necessary data for analysis are missing, we will attempt
contact with the corresponding author.
Quality and relevance assessment
Standard means of assessing quality in systematic reviews
are not appropriate for reviews of HSUVs, as they may
be at odds with the quality of the evidence reported. For
example, though randomized controlled trial data may be
the ‘gold standard’ for capturing treatment effects, such a
study design may be inferior when eliciting HSUVs due
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to low external validity or lack of relevance. There is lim-
ited guidance for assessing the quality of studies reporting
HSUVs. We use the hierarchy of data sources presented
by Cooper and colleagues [45] to rank studies from 1 to
6, as shown in Table 1. In order to enable researchers to
judge the quality of the study, our data extraction formwill
additionally record as follows: study sample size, inclu-
sion/exclusion criteria, response rates, loss to follow-up,
missing data, and the Cooper rank.
The relevance of studies to particular research ques-
tions may be more important than quality. For example,
the extent to which a study’s results can be used to
satisfy the NICE reference case may be crucial. Further-
more, the determinants of relevance may differ for future
users of the review. Our data extraction form will record
information that will enable users of the review to judge
the relevance of the reported HSUV, namely information
on interventions/comparators, inclusion/exclusion crite-
ria, country, age range, other sample specifics, valua-
tion method, and valuation source. There is currently no
accepted generalizable method for assessing the relevance
of HSUVs for a particular study. As such, these data will
be summarized qualitatively.
Data synthesis and presentation
All HSUVs and the characteristics of their associated stud-
ies will be tabulated. No qualitative synthesis of the data
Table 1 Cooper rank for utilities (reproduced from Cooper
et al. [45])
Rank Data components
1 Direct utility assessment for the specific study from a sample either:
(a) of the general population
(b) with knowledge of the disease(s) of interest
(c) of patients with the disease(s) of interest
Indirect utility assessment from specific study from patient
sample with disease(s) of interest, using a tool validated for the
patient population
2 Indirect utility assessment from a patient sample with disease(s) of
interest, using tool not validated for the patient population
3 Direct utility assessment from a previous study from a sample
either
(a) of the general population
(b) with knowledge of the disease(s) of interest
(c) of patients with the disease(s) of interest
Indirect utility assessment from previous study from patient
sample with disease(s) of interest, using a tool validated for the
patient population
4 Unsourced utility data from previous study - method of elicitation
unknown
5 Patient preference values obtained from a visual analog scale
6 Delphi panels, expert opinion
will be carried out. Saramago et al. identify that quanti-
tative synthesis of aggregate preference-based HSUVs is
limited by i) between-study heterogeneity in instruments
used, ii) the value set used to quantify utilities, and iii)
the models used to approximate scores for health states
[39]. Furthermore, a previous review, which reviewed
HSUVs associated with different visual acuity levels in
diabetic retinopathy, found variation in the methods of
elicitation [28]. It is important to measure the effect of
these methodological differences on HSUV estimates, and
meta-regression is the best way of doing this. Our prior
knowledge of the literature suggests that our review will
provide sufficient data to carry out an analysis of this
kind. Ameta-regressionmodel will enable us to predict an
expected HSUV for any given set of study characteristics.
For the most commonly used retinopathy grading sys-
tems, HSUVs will be pooled, with observations weighted
by the inverse of the variance of the mean HSUV, such
that:
Yi = yi
(
ni
σ 2i
)
, (1)
where yi is the observed average HSUV and Yi the
weighted average when ni is the number of respondents
and σ 2i the observed variance of yi. In order to address
the limitations of HSUV synthesis previously identified
[39], we will use linear mixed-effects modeling to account
for fixed and random effects associated with between-
study heterogeneity. This methodology is consistent with
previous studies [9,24]. The model will allow for ran-
dom variation on three levels: i) variation between mean
HSUVs across studies, ii) variation between mean HSUVs
across groups of individuals within studies, and iii) error
variation. Studies will report multiple HSUVs, so the
meta-regression will adopt a hierarchical approach such
that:
Yijk = β0 +
∑
h
βhxhijk + vi + uij + εijk , (2)
where Yijk is the weighted mean of the kth HSUV of the
jth group being estimated for study i, xijk are the variables
used to explain the between study heterogeneity, vi is the
random effects term of study i, uij is the random effects
term for the jth group of study i, and εijk is the random
error term with fixed variance to be estimated.
Predictor variables will be generated to include
retinopathy state, maculopathy state, publication year,
study design, country, valuationmethod, valuation source,
and administration method. We will explore the inclu-
sion of other covariates and will use a stepwise procedure
of model selection in order to reduce the likelihood of
errors. We will test for heteroscedasticity associated with
the inclusion of particular predictor variables. Covariates
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will only be included where the existing evidence sug-
gests that an association with the HSUV outcome might
exist. We will estimate variance inflation factors to test
for collinearity, and any strongly correlated variables will
be removed or collapsed if possible. Selection of variables
to be included in xijk in the final model will be informed
by Akaike’s information criterion. The base case will - as
far as possible - match the NICE reference case (that is,
use EQ-5D values) [6]. If a study does not have sufficient
data for inclusion in the model, the data will be assumed
missing at random and the study will be dropped from
the model. We will only carry out our proposed modeling
work if the data retrieved from the review are sufficient.
Additionally, we will attempt to map values to a dis-
ease state classification with four levels of retinopathy
and two levels of maculopathy. The mapped value for
each HSUV will be recorded using the data extraction
sheet and the mapping of the states will subsequently be
agreed with a clinician (DB). We will use the same regres-
sion methods described above to pool values based on
these classifications. We will estimate the intraclass corre-
lation coefficient associated with studies classified in this
way when no moderators are included, in order to quan-
tify the heterogeneity associated with such an approach.
Publication bias should not be of concern in a review
of HSUVs, as they are usually used as a secondary out-
come and therefore do not influence the likelihood of
publication.
Discussion
It is common for modeling studies to use utility values
from a single study deemed to be most relevant. Guide-
lines state that the choice of utility values should be
transparent and systematic. However, systematic reviews
are not common practice and this may result in biased
estimates of cost-effectiveness. By reporting all available
HSUVs alongside study characteristics, modelers will be
able to select themost appropriate value. Furthermore, the
results of themeta-regression will enable the estimation of
HSUVs based on specific criteria; for example those that
match the NICE reference case.
We will compare and contrast our findings with previ-
ously published reviews of HSUVs for diabetic retinopa-
thy. We will discuss the strengths and limitations and
highlight any apparent gaps in the identified evidence.
We will also identify the strengths and limitations of our
review and make suggestions for future research.
This protocol is the first of its kind to be published, and
the first to be registered prospectively. By creating a pub-
lic record of the intended review process it is possible to
maintain transparency in the process of selecting param-
eters to be used in decision analytic models of health
technologies. We hope that this approach will become
standard practice as part of the modeling process.
Additional files
Additional file 1: Appendix A: search terms. This document sets out
the search terms that we will use.
Additional file 2: Appendix B: data extraction form. This document
provides a screenshot of the electronic data extraction form that we will use.
Abbreviations
DR: Diabetic retinopathy; HSUV: Health state utility value; NDESP: NHS Diabetic
Eye Screening Programme; NHS: National Health Service (England); NICE:
National Institute for Health and Care Excellence; NPDR: Non-proliferative
diabetic retinopathy; PDR: Proliferative diabetic retinopathy; PRISMA: Preferred
reporting items for systematic reviews and meta-analyses; QALY:
Quality-adjusted life year.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CJS conceived the study, developed the methodology, and led the write-up.
JCT refined the review methodology and revised the manuscript. CPC
contributed to the design of the statistical methods and revised the
manuscript. DB helped determine the scope of the review, refined the search
strategy, and revised the manuscript. MJ helped to design the study and
revised the manuscript. All authors read and approved the final version of the
manuscript.
Acknowledgements
This article represents independent research funded by the National Institute
for Health Research (NIHR) under the Programme Grants for Applied Research
programme (RP-PG-1210-12016). The views expressed are those of the authors
and not necessarily those of the NHS, the NIHR, or the Department of Health.
Author details
1Division of Rehabilitation and Ageing, School of Medicine, University of
Nottingham, Queen’s Medical Centre, Nottingham, NG7 2UH, UK. 2School of
Health and Related Research, University of Sheffield, Regent Court, Sheffield,
S1 4DA, UK. 3Department of Biostatistics, University of Liverpool, Daulby Street,
Liverpool, L69 3GA, UK. 4Department of Eye and Vision Science, Royal
Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK.
Received: 16 October 2014 Accepted: 22 January 2015
References
1. Congdon N, O’Colmain B, Klaver CCW, Klein R, Muñoz B, Friedman DS,
et al. Causes and prevalence of visual impairment among adults in the
United States. Arch Ophthalmology. 2004;122(4):477–85.
2. Bunce C. Wormald R. Leading causes of certification for blindness and
partial sight in England & Wales. BMC Public Health. 2006;6:58.
3. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy:
a systematic review. JAMA. 2007;298(8):902–16.
4. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of
interventions to prevent and control diabetes mellitus: a systematic
review. Diabetes care. 2010;33(8):1872–94.
5. Kaltenthaler E, Tappenden P, Paisley S, Squires H. NICE DSU Technical
Support Document 13: Indentifying and reviewing evidence to inform
the conceptualisation and population of cost-effectiveness models. Tech.
rep. 2011.
6. National Institute for Health and Clinical Excellence. Guide to the
methods of technology appraisal. Tech. rep. National Institute for Health
and Clinical Excellence. 2008.
7. Tosh JC, Longworth LJ, George E. Utility values in National Institute for
Health and Clinical Excellence (NICE) Technology Appraisals. Value in
Health: J Int Soc Pharmacoeconomics Outcomes Res. 2011;14:102–9.
8. Brazier JE, Green C, Kanis JA. A systematic review of health state utility
values for osteoporosis-related conditions. Osteoporosis Int: A J
Sampson et al. Systematic Reviews  (2015) 4:15 Page 6 of 6
Established Result Cooperation between Eur Found Osteoporosis Nat
Osteoporosis Found USA. 2002;13(10):768–76.
9. Bremner KE, Chong CAKY, Tomlinson G, Alibhai SMH, Krahn MD.
A review and meta-analysis of prostate cancer utilities. Med Decision
Making: Int J Soc Med Decision Making. 2007;27(3):288–98.
10. Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic
pain: a systematic review and meta-analysis of health utilities. Pain.
2010;149(2):338–44.
11. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a
systematic review. Med Decision Making: Int J Soc Med Decision Making.
2008;28(4):582–92.
12. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med
Decision Making: Int J Soc Med Decision Making. 2002;22(6):475–81.
13. Peasgood T, Herrmann K, Kanis JA, Brazier JE. An updated systematic
review of Health State Utility Values for osteoporosis related conditions.
Osteoporosis Int: J established Result Cooperation between Eur Found
Osteoporosis Nat Osteoporosis Found USA. 2009;20(6):853–68.
14. Sturza J. A review and meta-analysis of utility values for lung cancer. Med
Decision Making: Int J Soc Med Decision Making. 2010;30(6):685–93.
15. Peasgood T, Ward SE, Brazier JE. Health-state utility values in breast
cancer. Expert Rev Pharmacoeconomics Outcomes Res.
2010;10(5):553–66.
16. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after
stroke: a systematic review of the literature. Stroke; J Cerebral Circulation.
2001;32(6):1425–9.
17. Lung TWC, Hayes AJ, Hayen A, Farmer A, Clarke PM. A meta-analysis of
health state valuations for people with diabetes: explaining the variation
across methods and implications for economic evaluation. Qual life Res:
an Int J Quality Life Aspects Treat, Care Rehabilitation.
2011;20(10):1669–78.
18. Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic
review and meta-analysis of utility-based quality of life in chronic kidney
disease treatments. PLoS Med. 2012;9(9):e1001307.
19. Bermingham SL, Ashe JF. Systematic review of the impact of urinary
tract infections on health-related quality of life. BJU Int.
2012;110(11 Pt C):E830–6.
20. Doyle S, Lloyd A, Moore L, Ray J, Gray A. A systematic review and critical
assessment of health state utilities. PharmacoEconomics. 2012;30(12):
1133–43.
21. van Litsenburg RRL, Kunst A, Huisman J, Ket JCF, Kaspers GJL, Gemke
RJBJ. Health status utilities in pediatrics: a systematic review of acute
lymphoblastic leukemia. Med Decision Making: Int J Soc Med Decision
Making. 2014;34:21–32.
22. Mohiuddin S, Payne K. Utility values for adults with unipolar depression:
systematic review and meta-analysis. Med Decision Making: Int J Soc Med
Decision Making. 2014;34(5):666–85.
23. Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility
values for economic modeling in type 2 diabetes. Value Health: J Int Soc
Pharmacoeconomics Outcomes Res. 2014;17(4):462–70.
24. Djalalov S, Rabeneck L, Tomlinson G, Bremner KE, Hilsden R, Hoch JS.
A review and meta-analysis of colorectal cancer utilities. Medical Decision
Making: Int J Soc Med Decision Making. 2014;34(6):809–18.
25. KinneyMR, Burfitt SN, Stullenbarger E, Rees B, DeBolt MR. Quality of life in
cardiac patient research: a meta-analysis. Nursing Res. 1996;45(3):173–80.
26. Dijkers M. Quality of life after spinal cord injury: a meta analysis of the
effects of disablement components. Spinal cord. 1997;35(12):829–40.
27. Meacock R, Dale N, Harrison MJ. The humanistic and economic burden
of systemic lupus erythematosus: a systematic review.
PharmacoEconomics. 2013;31:49–61.
28. Poku E, Brazier JE, Carlton J, Ferreira A. Health state utilities in patients
with diabetic retinopathy, diabetic macular oedema and age-related
macular degeneration: a systematic review. BMC Ophthalmology.
2013;13:74.
29. Brazier JE, Papaioannou D, Cantrell A. Identifying and reviewing health
state utility values for populating decision models In: Shemilt I, Mugford
M, Vale L, Marsh K, Donaldson C, editors. Evidence-based decisions and
economics: health care, social welfare, education and criminal justice. 2nd
ed. Oxford: Wiley-Blackwell; 2010. p. 93–105.
30. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review
of the economic evidence. Diabetic Med: J Br Diabetic Assoc.
2010;27(3):249–56.
31. Tosh J, Brazier JE, Evans P, Longworth LA. review of generic preference-
based measures of health-related quality of life in visual disorders. Value
Health. J Int Soc Pharmacoeconomics Outcomes Res. 2012;15:118–27.
32. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, Dills D,
Kampik A, Pararajasegaram R, Verdaguer JT. Proposed international
clinical diabetic retinopathy and diabetic macular edema disease severity
scales. Ophthalmology. 2003;110(9):1677–82.
33. NHS Diabetic Eye Screening Programme. http://diabeticeye.screening.
nhs.uk (2014). Accessed 2 Oct 2014.
34. Early Treatment Diabetic Retinopathy Study Research Group. Grading
diabetic retinopathy from stereoscopic color fundus photographs-an
extension of the modified airlie house classification. Ophthalmology.
1991;98(5):786–806.
35. Harding SP, Broadbent DM, Neoh C, White MC, Vora J. Sensitivity and
specificity of photography and direct ophthalmoscopy in screening for
sight threatening eye disease: the Liverpool Diabetic Eye Study. BMJ.
1995;311(7013):1131–5.
36. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group: Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. BMJ. 2009;b2535:339.
37. Papaioannou D, Brazier JE, Paisley S. NICE DSU Technical Support
Document 9: the identification, review and synthesis of health state utility
values from the literature. Tech. rep. 2011.
38. Papaioannou D, Brazier JE, Paisley S. Systematic searching and selection
of health state utility values from the literature. Value Health: J Int Soc
Pharmacoeconomics Outcomes Res. 2013;16(4):686–95.
39. Saramago P, Manca A, Sutton AJ. Deriving input parameters for
cost-effectiveness modeling: taxonomy of data types and approaches to
their statistical synthesis. Value Health: J Int Soc Pharmacoeconomics
Outcomes Res. 2012;15(5):639–49.
40. Kaltenthaler E, Tappenden P, Paisley S. Reviewing the evidence to inform
the population of cost-effectiveness models within health technology
assessments. Value Health. J Int Soc Pharmacoeconomics Outcomes Res.
2013;16(5):830–6.
41. Zechmeister-Koss I, Schnell-Inderst P, Zauner G. Appropriate evidence
sources for populating decision analytic models within health technology
assessment (HTA): a systematic review of HTA manuals and health
economic guidelines. Med Decision Making: Int J Soc Med Decision
Making. 2014;34(3):288–99.
42. SHERPA Search. http://www.sherpa.ac.uk/repositories/sherpasearchalluk.
html (2014). Accessed 3 Dec 2014.
43. RePEc. http://repec.org (2014). Accessed 3 Dec 2014.
44. Open Grey. http://www.opengrey.eu (2014). Accessed 3 Dec 2014.
45. Cooper NJ, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in
decision models: an appraisal of health technology assessments in the UK
since 1997. J Health Services Res Policy. 2005;10(4):245–50.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
